{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_mesalamine",
          "type": "Drug",
          "label": "Mesalamine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_budesonide",
          "type": "Drug",
          "label": "Budesonide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_prednisone",
          "type": "Drug",
          "label": "Prednisone",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_vedolizumab",
          "type": "Drug",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tofacitinib",
          "type": "Drug",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_sulfasalazine",
          "type": "Drug",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "Gastrointestinal_epithelial_barrier_disorders",
          "type": "Disease",
          "label": "Gastrointestinal epithelial barrier disorders",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_mesalamine",
          "type": "Target",
          "label": "OffTarget_Mesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_budesonide",
          "type": "Target",
          "label": "OffTarget_Budesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_prednisone",
          "type": "Target",
          "label": "OffTarget_Prednisone",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_azathioprine",
          "type": "Target",
          "label": "OffTarget_Azathioprine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "OffTarget_Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "OffTarget_Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ustekinumab",
          "type": "Target",
          "label": "OffTarget_Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_vedolizumab",
          "type": "Target",
          "label": "OffTarget_Vedolizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_tofacitinib",
          "type": "Target",
          "label": "OffTarget_Tofacitinib",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_methotrexate",
          "type": "Target",
          "label": "OffTarget_Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_sulfasalazine",
          "type": "Target",
          "label": "OffTarget_Sulfasalazine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp",
          "type": "Pathway",
          "label": "RiskPathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv",
          "type": "Phenotype",
          "label": "AdversePhenotype",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Mesalamine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Budesonide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Prednisone",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Azathioprine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Natalizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_natalizumab",
          "type": "Drug",
          "label": "Natalizumab",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_mesalamine",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已用于肠道炎症相关疾病"
        },
        {
          "source": "drug_budesonide",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "具有局部作用，常用于相关病症"
        },
        {
          "source": "drug_prednisone",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "经典免疫抑制剂，常用于肠道炎症"
        },
        {
          "source": "drug_azathioprine",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "用于长期免疫抑制，适用于相关疾病"
        },
        {
          "source": "drug_infliximab",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对特定类型肠道疾病的单克隆抗体"
        },
        {
          "source": "drug_adalimumab",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "适用于慢性肠道炎症病症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对肠道免疫调节有效"
        },
        {
          "source": "drug_vedolizumab",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "特定靶向治疗肠道疾病"
        },
        {
          "source": "drug_tofacitinib",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "小分子药物，有较好疗效"
        },
        {
          "source": "drug_methotrexate",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "应用于炎症性疾病的经典药物"
        },
        {
          "source": "drug_sulfasalazine",
          "target": "Gastrointestinal_epithelial_barrier_disorders",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "用于溃疡性结肠炎，有效性已证实"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_ot_mesalamine",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_budesonide",
          "target": "n_ot_budesonide",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_prednisone",
          "target": "n_ot_prednisone",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_azathioprine",
          "target": "n_ot_azathioprine",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_ustekinumab",
          "target": "n_ot_ustekinumab",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_vedolizumab",
          "target": "n_ot_vedolizumab",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_tofacitinib",
          "target": "n_ot_tofacitinib",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_methotrexate",
          "target": "n_ot_methotrexate",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "drug_sulfasalazine",
          "target": "n_ot_sulfasalazine",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "潜在的别靶作用"
        },
        {
          "source": "n_ot_mesalamine",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_budesonide",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_prednisone",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_azathioprine",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_ustekinumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_vedolizumab",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_tofacitinib",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_methotrexate",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_ot_sulfasalazine",
          "target": "n_rp",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路关联"
        },
        {
          "source": "n_rp",
          "target": "n_adv",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        },
        {
          "source": "n_adv",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "可能抵消疗效净获益"
        }
      ],
      "round_index": 1
    },
    "history": {
      "round": 1,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H1"
                ],
                "con": [
                  "H1"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Mesalamine 已用于肠道炎症相关疾病"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H2"
                ],
                "con": [
                  "H2"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Budesonide 具有局部作用，常用于相关病症"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H3",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H3"
                ],
                "con": [
                  "H3"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Prednisone 作为经典免疫抑制剂，适用于肠道炎症"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H4",
          "score": 0.54,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H4"
                ],
                "con": [
                  "H4"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Azathioprine 用于长期免疫抑制，适用于相关疾病"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H5",
          "score": 0.54,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H5"
                ],
                "con": [
                  "H5"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab 针对特定类型肠道疾病的单克隆抗体"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H6"
                ],
                "con": [
                  "H6"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab 适用于慢性肠道炎症病症"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H7"
                ],
                "con": [
                  "H7"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab 针对肠道免疫调节有效"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H8",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.4,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H8"
                ],
                "con": [
                  "H8"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Vedolizumab 适用于特定靶向治疗肠道疾病"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.5,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H9"
                ],
                "con": [
                  "H9"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Tofacitinib 作为小分子药物，有较好疗效"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.5,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H10"
                ],
                "con": [
                  "H10"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate 是用在炎症性疾病的经典药物"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.46,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.5,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H11"
                ],
                "con": [
                  "H11"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Sulfasalazine 用于溃疡性结肠炎，有效性已证实"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.46,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.5,
            "graph_bonus": 0.0,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Gastrointestinal epithelial barrier disorders",
                "pro": [
                  "H12"
                ],
                "con": [
                  "H12"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Natalizumab 用于免疫介导的疾病"
            ],
            "safety_risk": [
              "Skeptic 指出可能抵消疗效净获益的风险"
            ]
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏对潜在别靶作用的深入验证"
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "疗效净获益的风险",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_mesalamine",
            "via": [
              "n_ot_mesalamine"
            ],
            "to": "Gastrointestinal_epithelial_barrier_disorders",
            "success_criteria": "形成至少2条不相交路径，以提高评分",
            "assignee": "Proponent"
          },
          {
            "type": "merge_claims",
            "nodes": [
              "H1",
              "H2"
            ],
            "rationale": "对相关药物的疗效进行整合以减少冗余",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "评估疗效净获益与潜在别靶作用的影响",
          "如何构建可靠的机制链以提高 graph_bonus"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "疗效净获益的风险",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_budesonide",
            "via": [
              "n_ot_budesonide"
            ],
            "to": "Gastrointestinal_epithelial_barrier_disorders",
            "success_criteria": "形成至少2条不相交路径，以提高评分",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "评估疗效净获益与潜在别靶作用的影响",
          "如何构建可靠的机制链以提高 graph_bonus"
        ]
      },
      {
        "hypothesis_id": "H3",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "疗效净获益的风险",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_prednisone",
            "via": [
              "n_ot_prednisone"
            ],
            "to": "Gastrointestinal_epithelial_barrier_disorders",
            "success_criteria": "形成至少2条不相交路径，以提高评分",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "评估疗效净获益与潜在别靶作用的影响",
          "如何构建可靠的机制链以提高 graph_bonus"
        ]
      }
    ],
    "pruned_hypotheses": [],
    "new_subhypotheses": [],
    "seed_request": {
      "should_regenerate": true,
      "reason": "支持权重集中过低且冲突高，导致路径独立性不足，需引入更多作用机制的候选以改善图的连通性。",
      "n": 4
    }
  }
}